NYSE$ATR

AptarGroup Inc. · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

AptarGroup's Q4 2021 earnings report indicated revenue growth and adjusted EPS increase.

AptarGroup reported a 9% increase in sales, reaching $814 million, with core sales up 10%. Earnings per share increased by 8% to $0.85, and adjusted earnings per share rose by 3% to $0.93. Net income increased by 8% to $58 million.

  • Strong top line growth across each segment resulted in reported sales up 9% and core sales up 10%.
  • Reported earnings per share increased 8% to $0.85.
  • Adjusted earnings per share increased 3% to $0.93.
  • Reported net income increased 8% to $58 million.

Headline financials

Total Revenue

$814M

Previous: $749M+8.6%
EPS (adj)

$0.93

Previous: $0.92+1.1%
Total Core Sales Growth

10.0%

Previous: 5.0%+100.0%
Pharma Core Sales Growth

8.0%

Previous: 10.0%-20.0%
Beauty Core Sales Growth

7.0%

Previous: -2.0%+450.0%
Closures Core Sales Growth

28.0%

Previous: 13.0%+115.4%
Capital Expenditures

$91.2M

Previous: $72.6M+25.7%
Free Cash Flow

$12.8M

Previous: $116M-89.0%
Net Income

$58M

Previous: $53.2M+8.9%
Operating Income

$87.4M

Previous: $81.5M+7.2%
Gross Profit

$292M

Previous: $279M+4.7%
Cash & Equivalents

$123M

Previous: $300M-59.0%
Total Assets

$4.14B

Previous: $3.99B+3.8%
Stock-Based Comp

$9.15M

Previous: $7.96M+15.0%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$814M

Q4 2021+8.6%vs Q4 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

AptarGroup · $814M total across 3 segments · Q4 2021

  • Beauty
    $353M+4.8%
  • Pharma
    $332M+6.6%
  • Closures
    $129M+27.5%

Forward guidance

Aptar expects solid growth in the Pharma segment and continued recovery in the beauty and beverage businesses. Supply chain disruptions and currency headwinds are expected to continue in the near-term. The company expects earnings per share for the first quarter of 2022 to be in the range of $0.92 to $1.00.

Tailwinds

  • Solid growth expected in Pharma segment.
  • Prescription division expected to report growth in the allergy category.
  • Active material solutions demand for in-home COVID-19 antigen tests should be strong.
  • Beauty business continues to recover, especially in the prestige area.
  • Beverage business seeing signs of recovery.

Headwinds

  • Other COVID-19 variants may impact the pace of recoveries.
  • Supply chain disruptions are expected to continue in the near-term, primarily impacting our business in the U.S.
  • Currency headwinds may also continue in the near-term.
  • Rising input costs.
  • Effective tax rate range of 27% to 29% compared to first quarter of 2021 effective tax rate of 16% on adjusted earnings.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro